Seagen, amid deal rumors, spends $50M on a dual-targeting cancer drug

While a long-rumored acquisition by Merck & Co. still hasn’t materialized, Seagen is forging ahead with a deal of its own, grabbing rights to a bispecific antibody drug from Lava Therapeutics.